Dermavant’s PhIII eczema data; Oxford’s Nipah vaccine; Inventiva’s €25M lifelinenews2024-01-11T14:45:31+00:00January 11th, 2024|Endpoints News|
BioNTech pays $20M upfront for two monoclonal antibodies from China’s WuXi Biologicsnews2024-01-11T12:08:51+00:00January 11th, 2024|Endpoints News|
FDA approves import of French antibiotics to combat syphilis drug shortage news2024-01-11T11:10:49+00:00January 11th, 2024|Endpoints News|
#JPM24: Madrigal says it’s ‘well on the way’ to potential NASH launch ahead of FDA decisionnews2024-01-11T09:38:32+00:00January 11th, 2024|Endpoints News|
#JPM24: Cigna CEO says the insurance giant is paying attention to healthcare services to buynews2024-01-11T09:34:59+00:00January 11th, 2024|Endpoints News|
#JPM24 quick hits: Ionis on partnership’s pros and cons; Novo Ventures has $600M to spend; Are small molecules back? + morenews2024-01-10T23:06:29+00:00January 10th, 2024|Endpoints News|
#JPM24: Sanofi says it may look at next generation of weight loss drugsnews2024-01-10T22:43:43+00:00January 10th, 2024|Endpoints News|
How generic drug sponsors can ask FDA to reconsider applications: new draft guidance explainsnews2024-01-10T22:29:56+00:00January 10th, 2024|Endpoints News|
FDA commissioner says agency cannot be the only regulator of AI in digital healthnews2024-01-10T22:26:17+00:00January 10th, 2024|Endpoints News|
#JPM24: bluebird is still looking for more financing as it brings sickle cell therapy to marketnews2024-01-10T22:15:31+00:00January 10th, 2024|Endpoints News|
